The Novo Nordisk Foundation has come up with more funding to help battle the scourge of antimicrobial resistance (AMR), putting $25 million into a non-profit accelerator p
Innoviva has moved a step closer to bringing the first novel antibiotic to market for gonorrhoea in decades after reporting positive results in a phase 3 trial.
The FDA has given a green light to Innoviva’s antibiotic combination Xacduro, which becomes the first drug specifically approved for pneumonia caused by hard-to-treat bact
With cases of drug-resistant tuberculosis on the rise again around the world, GSK has sparked hopes of a new treatment option after reporting phase 2a data with a novel antitubercular drug
In an encouraging development for the fight against antimicrobial resistance (AMR), GSK's novel antibiotic gepotidacin has shown efficacy in two phase 3 trials, setting up regulatory filing
GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults
Health plans, employers, and healthcare providers remain committed to adopting digital solutions and expect to increase their spending on the category, according to a recent poll.